238 related articles for article (PubMed ID: 32660816)
1. Consistency of new drug pricing in Korea: Bridging variations among personnel in price negotiations.
Kwon HY; Kim J
Health Policy; 2020 Sep; 124(9):965-970. PubMed ID: 32660816
[TBL] [Abstract][Full Text] [Related]
2. Drug Pricing in South Korea.
Kwon HY; Godman B
Appl Health Econ Health Policy; 2017 Aug; 15(4):447-453. PubMed ID: 28138932
[TBL] [Abstract][Full Text] [Related]
3. Increasing Divergence in Drug Prices Between the United States and Germany After Implementation of Comparative Effectiveness Analysis and Collective Price Negotiations.
Berkemeier F; Whaley C; Robinson JC
J Manag Care Spec Pharm; 2019 Dec; 25(12):1310-1317. PubMed ID: 31778624
[TBL] [Abstract][Full Text] [Related]
4. Price negotiation and pricing of anticancer drugs in China: An observational study.
Zhou J; Lan T; Lu H; Pan J
PLoS Med; 2024 Jan; 21(1):e1004332. PubMed ID: 38166148
[TBL] [Abstract][Full Text] [Related]
5. Estimated Savings From Using Added Therapeutic Benefit and Therapeutic Reference Pricing in United States Medicare Drug Price Negotiations.
DiStefano MJ; Levy JF; Odouard IC; Anderson GF
Value Health; 2023 Nov; 26(11):1618-1624. PubMed ID: 37689264
[TBL] [Abstract][Full Text] [Related]
6. Determinants of price negotiations for new drugs. The experience of the Italian Medicines Agency.
Villa F; Tutone M; Altamura G; Antignani S; Cangini A; Fortino I; Melazzini M; Trotta F; Tafuri G; Jommi C
Health Policy; 2019 Jun; 123(6):595-600. PubMed ID: 31097207
[TBL] [Abstract][Full Text] [Related]
7. Promoting Access to Innovative Anticancer Medicines: A Review of Drug Price and National Reimbursement Negotiation in China.
Mingge X; Jingyu W; Qi L; Zhe Z; Qing R
Inquiry; 2023; 60():469580231170729. PubMed ID: 37171066
[TBL] [Abstract][Full Text] [Related]
8. Trends in the pricing and reimbursement of new anticancer drugs in South Korea: an analysis of listed anticancer drugs during the past three years.
Kim S; Kim J; Cho H; Lee K; Ryu C; Lee JH
Expert Rev Pharmacoecon Outcomes Res; 2021 Jun; 21(3):479-488. PubMed ID: 33275463
[No Abstract] [Full Text] [Related]
9. Progress on drug pricing negotiations in China.
Tang M; Song P; He J
Biosci Trends; 2020 Jan; 13(6):464-468. PubMed ID: 31875587
[TBL] [Abstract][Full Text] [Related]
10. From Indication-Based Pricing to Blended Approach: Evidence on the Price and Reimbursement Negotiation in Italy.
Rossini EE; Galeone C; Lucchetti C; Jommi C
Pharmacoecon Open; 2024 Mar; 8(2):251-261. PubMed ID: 38228997
[TBL] [Abstract][Full Text] [Related]
11. Prediction of Change in Prescription Ingredient Costs and Co-payment Rates under a Reference Pricing System in South Korea.
Heo JH; Rascati KL; Lee EK
Value Health Reg Issues; 2017 May; 12():7-19. PubMed ID: 28648319
[TBL] [Abstract][Full Text] [Related]
12. Assessing social preferences in reimbursement negotiations for new Pharmaceuticals in Oncology: an experimental design to analyse willingness to pay and willingness to accept.
Wettstein DJ; Boes S
BMC Health Serv Res; 2021 Mar; 21(1):234. PubMed ID: 33726735
[TBL] [Abstract][Full Text] [Related]
13. Financial Impact of Alternative Pricing Benchmarks for Physician-Dispensed Drugs in the California Workers' Compensation System.
Wilson L; Turkistani F; Tran DM; Huang W; Lin TK
Appl Health Econ Health Policy; 2019 Apr; 17(2):231-242. PubMed ID: 30484140
[TBL] [Abstract][Full Text] [Related]
14. How value-based policy interventions influence price negotiations for new medicines: An experimental approach and initial evidence.
Wettstein DJ; Boes S
Health Policy; 2022 Feb; 126(2):112-121. PubMed ID: 35000803
[TBL] [Abstract][Full Text] [Related]
15. [Access to medicines and South-South cooperation: a case study on joint drug price negotiations in South America].
Oliveira BNL; Oliveira MA
Cad Saude Publica; 2021; 37(10):e00170920. PubMed ID: 34730691
[TBL] [Abstract][Full Text] [Related]
16. The impact of early phase price agreements on prices of orphan drugs.
Nuijten M; Van Wilder P
BMC Health Serv Res; 2021 Mar; 21(1):222. PubMed ID: 33711994
[TBL] [Abstract][Full Text] [Related]
17. Role of Health Technology Assessment in Drug Policies: Korea.
Bae EY
Value Health Reg Issues; 2019 May; 18():24-29. PubMed ID: 30419447
[TBL] [Abstract][Full Text] [Related]
18. Health technology assessment-informed pricing negotiation in China: higher negotiated price for more effective targeted anticancer medicines?
Huang C; Ung COL; Wushouer H; Bai L; Huang T; Li X; Guan X; Shi L
Health Res Policy Syst; 2022 Jan; 20(1):3. PubMed ID: 34980159
[TBL] [Abstract][Full Text] [Related]
19. Lessons From The Impact Of Price Regulation On The Pricing Of Anticancer Drugs In Germany.
Lauenroth VD; Kesselheim AS; Sarpatwari A; Stern AD
Health Aff (Millwood); 2020 Jul; 39(7):1185-1193. PubMed ID: 32634355
[TBL] [Abstract][Full Text] [Related]
20. Reference Pricing in Germany: Implications for U.S. Pharmaceutical Purchasing.
Robinson JC; Panteli D; Ex P
Issue Brief (Commonw Fund); 2019 Feb; 2019():1-8. PubMed ID: 30883061
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
